These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29464550)

  • 1. Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.
    Srinivas N; Maffuid K; Kashuba ADM
    Clin Pharmacokinet; 2018 Sep; 57(9):1059-1074. PubMed ID: 29464550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics.
    de Lange ECM; van den Brink W; Yamamoto Y; de Witte WEA; Wong YC
    Expert Opin Drug Discov; 2017 Dec; 12(12):1207-1218. PubMed ID: 28933618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics.
    van den Brink WJ; Hankemeier T; van der Graaf PH; de Lange ECM
    Expert Opin Drug Discov; 2018 Jun; 13(6):539-550. PubMed ID: 29519169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.
    de Lange EC; Ravenstijn PG; Groenendaal D; van Steeg TJ
    AAPS J; 2005 Oct; 7(3):E532-43. PubMed ID: 16353931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.
    Ball K; Bouzom F; Scherrmann JM; Walther B; Declèves X
    Biopharm Drug Dispos; 2014 Nov; 35(8):485-99. PubMed ID: 25044007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation.
    Caruso A; Alvarez-Sánchez R; Hillebrecht A; Poirier A; Schuler F; Lavé T; Funk C; Belli S
    Biochem Pharmacol; 2013 Jun; 85(11):1684-99. PubMed ID: 23454189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of brain barriers in the neurokinetics and pharmacodynamics of lithium.
    Luo H; Chevillard L; Bellivier F; Mégarbane B; Etain B; Cisternino S; Declèves X
    Pharmacol Res; 2021 Apr; 166():105480. PubMed ID: 33549730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach.
    Yamamoto Y; Välitalo PA; Wong YC; Huntjens DR; Proost JH; Vermeulen A; Krauwinkel W; Beukers MW; Kokki H; Kokki M; Danhof M; van Hasselt JGC; de Lange ECM
    Eur J Pharm Sci; 2018 Jan; 112():168-179. PubMed ID: 29133240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of CSF in translational neuroscience.
    de Lange EC
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):315-26. PubMed ID: 23400635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds.
    Alavijeh MS; Palmer AM
    Neurobiol Dis; 2010 Jan; 37(1):38-47. PubMed ID: 19818851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs.
    Alqahtani S; Kaddoumi A
    Clin Pharmacokinet; 2016 Aug; 55(8):957-69. PubMed ID: 26914771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
    Sahu JK; Mishra AK
    Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of predictive models in CNS diseases.
    Gomeni R
    Curr Opin Pharmacol; 2014 Feb; 14():23-9. PubMed ID: 24565008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling of PET data in CNS drug discovery and development.
    Varnäs K; Varrone A; Farde L
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):267-79. PubMed ID: 23660778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development.
    Geerts H; Spiros A; Roberts P; Carr R
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):257-65. PubMed ID: 23338980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations.
    Saleh MAA; Loo CF; Elassaiss-Schaap J; De Lange ECM
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):725-741. PubMed ID: 34142308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics-pharmacodynamics of antifungal agents in the central nervous system.
    Stott KE; Hope W
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):803-815. PubMed ID: 29943650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral microdialysis in clinical studies of drugs: pharmacokinetic applications.
    Shannon RJ; Carpenter KL; Guilfoyle MR; Helmy A; Hutchinson PJ
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):343-58. PubMed ID: 23468415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropharmacokinetics: a bridging tool between CNS drug development and therapeutic outcome.
    Chaturvedi S; Rashid M; Malik MY; Agarwal A; Singh SK; Gayen JR; Wahajuddin M
    Drug Discov Today; 2019 May; 24(5):1166-1175. PubMed ID: 30898661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microdialysis for pharmacokinetic-pharmacodynamic studies.
    Yu W; Cheng Q; Feng J; Li F
    Pharmazie; 2007 Dec; 62(12):883-91. PubMed ID: 18214337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.